Your session is about to expire
← Back to Search
Instylla HES for Cancer Embolization Treatment
Study Summary
This trial is comparing Instylla HES to standard of care transarterial embolization/conventional transarterial chemoembolization to see if it is effective and safe.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had radioembolization on the tumor area within the last 30 days.You have ongoing health issues or complications from previous treatments that may not benefit from participating in the study or could potentially put your safety at risk. This includes conditions like ongoing infections, kidney problems, severe obesity, or serious heart disease.My tumor is hypervascular and I need a specific artery-blocking treatment.I am 22 years old or older.I have a tumor in my adrenal gland.I can care for myself and am up and about more than 50% of my waking hours.Not all my blood vessels needing treatment can be treated with standard methods.I have severe liver disease or a complete blockage in the liver's main blood vessel.I understand the study details and have signed the consent form.My tumor is larger than 8 cm or makes up more than half of the affected organ.I have had embolization for conditions other than blood-rich tumors.My target lesion is supplied by major arteries or connected to them.I have a blood vessel smaller than 5mm that can be treated with Instylla HES.I am scheduled for another procedure on the same day as my main surgery.I need a specific liver tumor treatment through an artery outside the liver.I have severe artery disease that prevents catheter use.My last Avastin dose was within the last 4 weeks.I am not pregnant, breastfeeding, nor planning to become pregnant soon.My cancer has spread to my bones.I have a kidney tumor, whether it's primary, metastatic, or benign.I have a tumor that has a lot of blood vessels.Your doctor believes you will live for at least 6 more months after the embolization procedure.My liver cancer cannot be removed by surgery.I am receiving specific liver cancer treatments.I have had surgery or procedures on my bile ducts, including stents or sphincterotomy.
- Group 1: Control
- Group 2: Instylla HES
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have been accepted into this research program?
"To carry out this scientific endeavour, 150 patients who meet the inclusion requirements need to be identified. Instylla, Inc., is managing the trial from a number of centres such as Boston Medical Center in Massachusetts and Northwell Health, Inc. located in Manhasset, New york."
Are there any centers in the US that are currently undertaking this research?
"Boston Medical Center in Boston, Massachusetts, Northwell Health Inc. in Manhasset, New york and University of Colorado Anschutz Medical Center in Aurora, Colorado are just 3 out the 17 clinical trial sites delivering this treatment."
Are there any slots still available for this experiment?
"According to information found on clinicaltrials.gov, this research project is presently looking for test subjects. The trial was initially uploaded on April 1st 2021 and the last update occurred November 4th 2022."
Share this study with friends
Copy Link
Messenger